Literature DB >> 10749584

High production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines.

Y Kato1, F Frankenne, A Noël, N Sakai, Y Nagashima, S Koshika, K Miyazaki, J M Foidart.   

Abstract

Production of SPARC/osteonectin/BM-40 was determined in mouse B16 melanoma clones BL6 and F10 (high metastatic) and F1 (low metastatic). SPARC was produced greater amount in BL6 and F10 than in F1 cells, showing a good agreement with their metastatic potentials. Moreover, SPARC production was not influenced by culture pH, even in the acidic conditions (= pH 5.9). Although tumor tissues show often low pH due to excessive amount of acidic metabolites such as lactate, most studies have been done in neutral pH. High SPARC production in the acidic medium, therefore, is thought to be an important potential for tumor invasive behaviour.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749584     DOI: 10.1007/bf03032654

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  21 in total

1.  SPARC: a potential diagnostic marker of invasive meningiomas.

Authors:  S A Rempel; S Ge; J A Gutiérrez
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma.

Authors:  B Le Bail; S Faouzi; L Boussarie; J Guirouilh; J F Blanc; J Carles; P Bioulac-Sage; C Balabaud; J Rosenbaum
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

3.  Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens.

Authors:  T Sasaki; W Göhring; K Mann; P Maurer; E Hohenester; V Knäuper; G Murphy; R Timpl
Journal:  J Biol Chem       Date:  1997-04-04       Impact factor: 5.157

4.  Osteonectin, a bone-specific protein linking mineral to collagen.

Authors:  J D Termine; H K Kleinman; S W Whitson; K M Conn; M L McGarvey; G R Martin
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

5.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.

Authors:  D Massi; A Franchi; L Borgognoni; U M Reali; M Santucci
Journal:  Hum Pathol       Date:  1999-03       Impact factor: 3.466

6.  Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone.

Authors:  K Jacob; M Webber; D Benayahu; H K Kleinman
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

7.  Slow induction of gelatinase B mRNA by acidic culture conditions in mouse metastatic melanoma cells.

Authors:  Y Kato; S Ozono; T Shuin; K Miyazaki
Journal:  Cell Biol Int       Date:  1996-05       Impact factor: 3.612

8.  Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes.

Authors:  H Porte; E Chastre; S Prevot; B Nordlinger; S Empereur; P Basset; P Chambon; C Gespach
Journal:  Int J Cancer       Date:  1995-02-20       Impact factor: 7.396

9.  Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines.

Authors:  Y Kato; Y Nakayama; M Umeda; K Miyazaki
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

View more
  2 in total

1.  SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Authors:  Houda Alachkar; Ramasamy Santhanam; Kati Maharry; Klaus H Metzeler; Xiaomeng Huang; Jessica Kohlschmidt; Jason H Mendler; Juliana M Benito; Christopher Hickey; Paolo Neviani; Adrienne M Dorrance; Mirela Anghelina; Jihane Khalife; Somayeh S Tarighat; Stefano Volinia; Susan P Whitman; Peter Paschka; Pia Hoellerbauer; Yue-Zhong Wu; Lina Han; Brad N Bolon; William Blum; Krzysztof Mrózek; Andrew J Carroll; Danilo Perrotti; Michael Andreeff; Michael A Caligiuri; Marina Konopleva; Ramiro Garzon; Clara D Bloomfield; Guido Marcucci
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

2.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.